Evaluation of the influence of intravenous carnitine on hemoglobin and hematocrit levels in end stage chronic renal failure patients under hemodialysis

Journal of Zanjan University of Medical Sciences and Health Services

Volumn 18, Issue 73, 2010, Pages 58-66

  Khodaverdi, M ^a   Zamzami, E ^b   Mousavinasab, S N ^a   Khodaverdi, S ^c   Amirmoghadami, H R ^d   Ahmadi, J ^e  

^a ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anemia; Chronic renal failure; Hemodialysis; Intravenous carnitine

Indexed keywords

CARNITINE; HEMOGLOBIN; PLACEBO;

ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; MALE;

EID: 78650119349     PISSN: 16069366     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Strippoli GF, Manno C, Schena FP, Craiy JC.Hemoglobin and hematocrit targets for the anemia of chronic renal disease. Available from: URl: Http:// www.ncbi.nlm.nih. gov/pubmed/12535495.
2. Nissenson AR, Fine RN. Dialysis therapy. Philadelphia: Hanley & Belfus; 2002.
3. Lilien MR, Durun M, Quak JM, Frank huisen JJ, Schroder CH. Oral L-carnitine doesnot decrease erythropoietin requirement in pediatric disease. Pediatr Nephrol 2000; 15: 17-20.
4. Bellinghieri G, Santoro D, Calvani M, Mmalamace A, Savica V. Carnitine and hemodialysis. Am J Kidney Dis. 2003; 41: 5116-22.
5. Debska - Slizien A, Owczarzak A, Kunicka D, Lysiacszydlowska W, Rutkowski B. Plasma carnitine profile during chronic renal anemia treatment with recombinant human erythropoietin. Int J Artif Organ 2003; 26: 33-8.
6. Massry SG, Classock RJ. Massry & Glassoch's Text book of nephrology. Philadelphia: LWW; 2001
7. Matsumura M, Hatakeyama S, Koni I, et al. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephrol. 1996 ;72: 574-8.
8. 8- Arduini A, Holm S, Sweeney JD, Dottori S, Sciarroni AF, Calvani M. Addition of L-carnitine to additive solution suspended red cells stored at 4·c reduces in vitro hemolysis and improves in vivo viability. Transfusion. 1997; 37: 166-74. (Pubitemid 27091902)
9. Thomas S, Fischer F, Mettang T, Pauli-Magnus C, Weber J, Kuhlmann V. Effects of L-carnitine on leukocyte function and viability in Hemodialysis patients:A double-blind randomized trial. Am J Kidney Dis. 1999; 34: 678-87.
10. Hardman JG, Limbird LE, Goodman& Gilman S. The pharmacological basis of theraputics. New York: MCGraw - Hill; 2001.
11. Trovato GM, Ginardi V, Dimarco V, Dell Aira A. Long term L-carnitine treatment of chronic anemia of patients with end-stage renal failure. Currther Res. 1982; 31: 1042-9.
12. Ahmad S. L-carnitine in dialysis patients. Science. 2001; 14: 209-17.
13. Steinman TI, Nissen Son AR, Glassock RJ, et al. L-carnitine use in dialysis patients is national coverage for supplementation carnitine levels and erythrocyte osmotic justified. Nephrol News Issues. 2003; 17: 28-30.
14. Nikolas S, George A, Telemacho ST, Maria S, Yannis M, Konstantino M. Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients. Red Fail. 2000; 22: 73-80.
15. Matsumoto Y, Amano I, Hirose S, et al. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif. 2001; 19: 24-32.
16. Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis. 1999; 34: 400-1.